

Index

- A**
- AIDS
associated complications 42
- albendazole 177, 220, 222
- amoeba 1
Acanthamoeba 1
Balamuthia 1
Endolimax 1
Entamoeba 1
Iodamoeba 1
Naegleria 1
- amoeba, free living 8
Acanthamoeba spp 8
Balamuthia madrillaris 8
Naegleria fowleri 8
- amoeba, nonpathogenic
Endolimax nana 1, 7
Entamoeba coli 1, 7
Entamoeba chattoni 1
Entamoeba dispar 1
incidence of amebiasis 2–3
Entamoeba hartmanni 1, 7
Entamoeba invadens 1
Entamoeba moshkovskii 1
Entamoeba polecki 1
Iodamoeba butschlii 1, 7
- amoeba, pathogenic
Entamoeba histolytica 2
clinical significance of 3–5
incidence of amebiasis 2–3
morphology of 3
pathogenesis and immunity 5–6
therapy 6
- amoebic colitis 4
- amoebic dysentery 3
- amoebicides
albendazole 177, 220, 222
chloroquine 6
dehydroemetine 6
diloxanide furate 6
furazolidone 27
iodoquinol 6–7, 11
ketoconazole cream 8
mebendazole 7, 177
metronidazole 6, 11
ornidazole 27
secnidazole 27
triclabendazole 186
- Angiostrongylus cantonensis* 148–150
- Angiostrongylus costaricensis* 148–150
- anisakid worms 146
- Anisakis Simplex* 135, 145
background 145
clinical manifestations 147
control 148
diagnosis 147–148
epidemiology 146–147
life cycle 146
prevention 148
treatment 147–148
- apicomplexan parasites, *see* *Cryptosporidium* spp
- B**
- BioTechnology Frontiers, (BTF) 255
- bithionol 167, 181, 186
- Blastocystis* 1
- C**
- Catostomus commersoni* 173
- cestodes, *see* tapeworms
- cholangiocarcinoma 172
- ciliates 1, 8
Balantidium coli 1
clinical significance 9–11
diagnosis and treatment 11
epidemiology and prevention 11
life cycle and morphology 9
- ciprofloxacin 46
- CLB, *see* coccidian parasites
- Clonorchis* eggs 161
- coccidian parasites, *see also* *Toxoplasma gondii*
background of 33–35
differences between species 35
biology 36–38
human infections 36–38
life cycle of 36
clinical significance 38–39
diagnosis methods 45–46
enzyme-linked immunosorbent assay (ELISA) 46
indirect fluorescent antibody technique (IFAT) 46
oligonucleotide-ligation assay (OLA) 46
- real-time polymerase chain reaction 46
- foodborne outbreaks 39–40
- transmission and epidemiology
Cyclospora cayetanensis 39–42
Iso spor a belli 42
Sarcocystis spp 42–45
treatment and control 46–47
- Cryptosporidium* spp.
232–235
control of contamination 82–86
chlorination 82
ozone and ultra violet radiation 82, 84
physical removal 82
snap freezing 84
- cryptosporidiosis
transmission 57
- cryptosporidiosis outbreaks 233
- currently recognized 59
- diagnosis and detection
antigen detection by immunoassays 73–74
EPA method 80–81
indirect fluorescent antibody technique (IFAT) 77–78
microscopic detection of stool specimens 70–73
molecular method 74–77
polymerase chain reaction method 78–80
serologic method 69
- epidemiology
cryptosporidiosis in immunocompetent persons 61–62
cryptosporidiosis in immunocompromised persons 62–63
- life cycle and developmental biology 60–61
- taxonomy of 57
C. andersoni 58
Cryptosporidium canis 58

- Cryptosporidium* (cont.)
- Cryptosporidium felis* 58
 - Cryptosporidium hominis* 58
 - Cryptosporidium meleagridis* 58
 - Cryptosporidium muris* 58
 - Cryptosporidium suis* 58
 - Cryptosporidium wrairi* 58
- transmission routes and infection sources
- anthroponotic versus zoonotic 63–64
 - food 66–69
 - water 64–66
- treatment
- paramomycin 81
 - spiramycin 81
- Cyclospora cayetanensis* 33, 39–42
- cysteine proteinases 5
- cysticercosis 201–202
- D**
- 4,6 diamidino-2'-phenylindole 239
- Dientamoeba fragilis*
- morphology and transmission 6–7
 - therapy 7
- digenetic trematodes 161
- Clonorchis sinensis* 168
 - clinical signs 171–173
 - diagnosis 171–173
 - epidemiology 170–171
 - hosts for 170
 - life cycle 169–170
 - treatment 171–173
 - comparison of food-borne 162
 - Fasciolopsis buski*
 - clinical signs 188–189
 - diagnosis 188–189
 - epidemiology 188
 - life cycle 187–188
 - treatment 188–189
 - Fasciola gigantica*
 - clinical signs 184–186
 - diagnosis 184–186
 - epidemiology 184
 - life cycle 182–184
 - treatment 184–186
 - Fasciola hepatica*
 - clinical signs 184–186
 - diagnosis 184–186
 - epidemiology 184
 - life cycle 182–184
- treatment 184–186
- Nanophyetus salmincola*
- clinical signs 180–182
 - diagnosis 180–182
 - life cycle 177–179
 - salmon poisoning
 - disease 179–180
 - treatment 180–182
- Opisthorchis felineus* 174
- clinical signs 176–177
 - diagnosis 176–177
 - epidemiology 175
 - life cycle 174–175
 - treatment 176–177
- Opisthorchis viverrini* 174
- clinical signs 176–177
 - diagnosis 176–177
 - epidemiology 175
 - life cycle 174–175
 - treatment 176–177
- Paragonimus* spp 161
- clinical signs 166–168
 - diagnosis 166–168
 - epidemiology 165–166
 - life cycle 163–165
 - treatment 166–168
- prevention and control of 189–191
- agricultural practices 190
 - cooking time 190
 - drying 190
 - freezing 190
 - pickling 190
 - salting 190
 - smoking 190
- Diphyllobothrium* spp
- Diphyllobothrium latum*
 - biology 211–212
 - clinical aspects 213–214
 - control 214
 - diagnosis 213–214
 - epidemiology 212
 - transmission 213
 - treatment 214
 - Diphyllobothrium pacificum*
 - clinical presentation 215
 - control 215
 - diagnosis 215
 - epidemiology 214
 - life cycle 214
 - transmission 214
- DMSO-carbolfuchsin 238
- E**
- Echinococcus* spp
- Echinococcus granulosus*
 - biology 216–217
 - clinical aspects 218–219
 - control 220–221
 - diagnosis 219–220
 - epidemiology 217–218
 - treatment 220
 - Echinococcus multilocularis*
 - biology 221
 - clinical relevance 222
 - control 223
 - diagnosis 222
 - epidemiology 221–222
 - transmission 222
 - treatment 222–223
- EhPgp1* 6
- Entamoeba gingivalis* 1
- enteric tract infection, of humans, *see* coccidian parasites
- eosinophilic meningitis, *see* *Angiostrongylus cantonensis*; *Angiostrongylus costaricensis*
- F**
- flagyl, *see* metronidazole
- fluconazole 8
- fluorescence *in situ* hybridization (FISH) 251
- fluorescent dye stains
- acridine orange 238
 - diamidino-2'-phenylindole (DAPI) 238, 250
 - propidium iodide (PI) and 4, 6, 238
- food borne parasites, risk assessment of
- framework 276
 - assumptions 281–282
 - defining hazard 276
 - exposure assessment 277–278
 - hazard characterization 278–280
 - risk assessment 282
 - risk characterization 280–281
 - by National Research Council 275
- furazolidone 27
- G**
- Gal/GalNAc lectin 5
- Giardia intestinalis* 15
- biology of 16
 - classification methods 19–20
 - polymerase chain reaction (PCR) method 19

- Pulsed field gel electrophoresis (PFGE) 19
restriction fragment length polymorphisms (RFLPs) 19
zymodeme analysis 19
control and treatment 25–27
detection methods 17
 enzyme immunoassays (EIA) 17
 immunofluorescent antibody microscopy (IFA) 17
 US EPA method 19
genotyping of 20–23
 TPI genes 20
host range of 16
taxonomy of 17
transmission and epidemiology
 environmental 24–25
 human 23–24
Gnathostoma spp. 150–151
Gnathostomiasis, *see* *Gnathostoma* spp
Gongylonema pulchrum 151–152
GRA4 genes 114
granulomatous amoebic encephalitis (GAE) 8
- H**
hazard analysis critical control point (HACCP) programs 275, 278, 282
Hymenolepis spp
 Hymenolepis nana
 biology 223
 clinical aspects 225
 control 225
 diagnosis 225
 epidemiology 224
 transmission 224
 treatment 225
- I**
immunomagnetic separation (IMS) 237
Invader[®] technology 248
Isospora belli 33, 42
- K**
ketoconazole cream 8
- L**
Laboratory Multi-Analyte Profiling 248
Ligase Chain Reaction 248
- M**
macrogametocytes 111
mebendazole 177
merogony 60
meronts, types of 60
metastrongyle nematodes, *see* *Angiostrongylus cantonensis*; *Angiostrongylus costaricensis*
metronidazole 27
monoxenus parasites, *see* *Cyclospora cayetanensis*; *Isospora belli*
- N**
nematode infection parasites, food-borne 135
 Angiostrongylus cantonensis 148–150
 Angiostrongylus costaricensis 148–150
 Anisakis simplex, *see* *Anisakis simplex*
 Gnathostoma spp 150–151
 Gongylonema pulchrum 151–152
 Trichinella, *see* *Trichinella*
neurocysticercosis, criteria for diagnosis of 205
niclofolan 168
niclosamide 181, 206, 209, 211, 214
nitoxozanide 27
Nomarski differential interference contrast microscopy (DIC) 237
nucleic acid liberating schemes 242–243
nucleic acid sequence-based amplification (NASBA) 248
nurse cell 137
- O**
ornidazole 27
- P**
PAIR treatment 220
parasite concentration and isolation technique 235–237
parasite detection methodologies
 advantages of 240–241
 disadvantages 240–241
 evaluation of 253–255
 good laboratory practices (GLP) 253
 lower limit of detection (LLOD) 253
 thrombospondin-related anonymous protein (TRAP) gene, use of 254
immunological-based techniques
 speciation and genotyping techniques 249–250
 strengths and weaknesses 248–249
microscopic techniques
 dye stains 238
 fluorescent labeling 238
 strengths and weaknesses 237–238
 USEPA approved 239
nucleic acid techniques
 DNA based protocols 243–247
 nucleic acid recovery techniques 242–243
 RNA based protocols 248
 strengths and weaknesses 239–242
viability techniques
 cell culture and animal infectivity models 252
 dye permeability assays 250
 fluorescence *in situ* hybridization (FISH) 251
 in vitro excystation 251
 reverse transcription PCR 251
 strengths and weaknesses 250
Percoll/Percoll step gradient 237
Percoll/sucrose flotation 237
phosphate buffered saline (PBS) 235
polymerase chain reaction (PCR) 6, 243–244
 multiplex 247
 nested 244
 real-time 246
 reverse transcription 248
praziquantel 167, 173, 177, 181, 186, 189, 206, 209, 211, 214, 220, 225
protozoan parasites
 amoeba 1
 axenic cultivation of 2

- protozoan parasites (*cont.*)
 life cycle of 2
 nonpathogenic, *see* amoeba,
 amoeba,
 nonpathogenic
 pathogenic, *see* amoeba,
 pathogenic
 ciliates 1
 food-borne, of human
 concern 277
 pyrimethamine therapy 46
- Q**
 Q-beta replicase 248
 quinacrine 27
- R**
 18S rRNA gene 254
- S**
 Safe Drinking Water Act 18–19
 safranin methylene blue stain
 238
 SAG1-4 genes 114
 SAG5A genes 114
 SAG5B genes 114
 SAG5C genes 114
 Sanitary and Phyto-Sanitary
 (SPS) Agreement, of WTO
 and GATT 275
 Sarcocystis hominis 33, 42–
 45
 Sarcocystis spp infection, in
 countries
 Belgium 44
 Brazil 43, 45
 Canada 44
 Czechoslovakia 43–44
 Ethiopia 44
 Ghana 44
 Hanoi-Haiphong areas
 43
 India 44
 Iran 44
 Japan 44
 Malaysia 43
 Mongolia 44
 New Zealand 44
 Thailand 42
 Tibet 43
 Sarcocystis suihominis 33,
 42–45
 Schistosoma eggs 161
 secnidazole 27
 selective centrifugation
 techniques *see* parasite
 concentration and isolation
 technique
 Spirometra spp
 Spirometra mansoides
 biology 215
 clinical aspects 216
 control 216
 diagnosis 216
 epidemiology 215
 transmission 215–216
 treatment 216
 SSU-rRNA gene 46
 sulfadiazine 8
- T**
 Taenia spp.
 T. asiatica 197, 209
 biology 210
 clinical aspects
 210–211
 control 211
 diagnosis 210–211
 epidemiology 210
 transmission 210
 treatment 211
 T. saginata 197
 biology 207–208
 clinical aspects
 208–209
 control 209
 diagnosis 208–209
 epidemiology 208
 transmission 208
 treatment 209
 T. solium 197
 biology of 198–200
 clinical aspects
 202–204
 control 207
 diagnosis 204–206
 epidemiology 200–201
 transmission 201–202
 treatment 206–207
 tapeworms 197
 Diphyllbothrium spp., *see*
 Diphyllbothrium spp
 Echinococcus spp., *see*
 Echinococcus spp
 Hymenolepis spp., *see*
 Hymenolepis spp
 Spirometra spp., *see*
 Spirometra spp
 Taenia spp., *see* Taenia spp.
 tetracycline 11
 Toxoplasma gondii
 epidemiology
 in humans 115–118
 in other animal species
 122–123
 in poultry 120–121
 in sheep and goats
 121–122
 in swine 118–120
 identification 112
 molecular assays
 113–114
 PCR-RFLP method 115
 ribotyping 114–115
 inactivation 124–125
 infection 109
 life cycle of 110–112
 pathogenicity 115
 transmission of 112
 treatment
 azithromycin 124
 nifurtimox 124
 pyrimethamine 123
 sulfadiazine 123
 types of 110
 Toxoplasma infection, in
 humans
 in crowded conditions
 116
 in Ethiopian immigrants
 117
 in Netherlands 117
 in Slovenia 118
 in South America 118
 in Spain 117
 in Tanzania 117
 women 115
 in Catania 116
 in India 116
 in Korea 116
 in Sweden 117
 transcription mediated
 amplification (TMA) 248
 Trichina spiralis, *see*
 Trichinella
 Trichinella 135
 background 135
 clinical manifestations
 142–143
 control 143–145
 diagnosis 143
 epidemiology
 Trichinella brivoti 138
 Trichinella murrelli 139
 Trichinella native 138
 Trichinella nelsoni 139
 Trichinella papuae 139
 Trichinella
 pseudospiralis 139
 Trichinella spiralis 138
 Trichinella T6 140
 Trichinella T8 and T9
 140
 Trichinella
 zimbabwensis 140
 human trichinellosis
 infection 140–142
 due to globalization 141
 ecological modification
 142
 human behavior 141
 literacy level 141
 misdiagnosis 142

life cycle 136–137
prevention 143–145
speciation 136
transmission routes 140
treatment 143
triclabendazole 186
trimethoprim sulfamethoxazole
(TMPSMX) 46
triose phosphate isomerase
(TPI) gene 17
trophozoites 1, 16

U

ulcers 3

US Environmental Protection
Agency (USEPA)-mandated
Information Collection Rule
(ICR) 236
USEPA Method 1623 236

W

waterborne parasites
Ascaris lumbricoides 232
Ascaris suum 232
Balantidium coli 232
Blastocystis hominis 232
Cyclospora cayetanensis
232

Cryptosporidium parvum
231–232

Fasciolopsis buski
232

Fasciola hepatica 232

Giardia lamblia 231–232
235

Toxoplasma gondii 232

Wisconsin State Laboratory of
Hygiene Flow Cytometry
Unit (WSLH) 255

Z

zymodeme analysis 6